Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Let's take a look at the top stories in biotech and health care this morning -- keep an eye out for Actavis plc (NYSE: ACT  ) , DepoMed (NASDAQ: DEPO  ) and Horizon Pharma (NASDAQ: HZNP  ) . 

Actavis to sell generic Celebrex
After a court ruling yesterday, Pfizer's (NYSE: PFE  ) fourth best-selling drug Celebrex may now come off of patent protection as early as this May, although Pfizer (NYSE: PFE  ) will appeal the ruling. And Actavis (NYSE: ACT  ) plans on being among the first to offer a generic version of the megablockbuster painkiller. Although Celebrex saw sales of approximately $3 billion last year, generic manufacturers, like Actavis (NYSE: ACT  ) , will face stiff competition. Specifically, five companies have already been identified as players in the race to manufacture generic Celebrex. So, although Actavis (NYSE: ACT  ) will certainly benefit from the court's decision to invalidate a patent that would have extended the drug's patent protection until 2016, it's hard to see how any one company will necessarily be gaining a lion's share of the generic Celebrex pie. As such, I don't think this news will be a major event for Actavis (NYSE: ACT  ) moving forward.  

DepoMed continues to rally after earnings? 
Shares of DepoMed (NASDAQ: DEPO  ) are up over 6% in premarket this morning after management provided some color on the company's stronger than expected fourth quarter earnings report. Specifically, DepoMed (NASDAQ: DEPO  ) crushed the Street's estimates yesterday for both earnings and revenue. Revenue beat estimates by over 100% and earnings per share beat by 27%.

Although better than expected sales of Gralise and Zipsor contributed to the beat, the bulk of it can be attributed to a deal with PDL Biopharma (NASDAQ: PDLI  )  for future royalty and milestone payments in the company's diabetes franchise. Per the terms of the deal, DepoMed (NASDAQ: DEPO  ) received $240.5 million in exchange for interests in future royalty and milestone payments in the Type 2 diabetes therapeutic area. DepoMed (NASDAQ: DEPO  ) recognized $18.1 million of non-cash revenues and $4.5 million in non-cash interest expense under this arrangement in the fourth quarter.

What really stands out in this earnings report, however, is the company's strong 2014 guidance. Namely, DepoMed (NASDAQ: DEPO  ) expects total revenues to increase by over 400% this year, mostly due to the deal with PDL Biopharma (NASDAQ: PDLI  ) . So, there is good reason to keep tabs on DepoMed going forward. 

Horizon beats on revenue but misses on earnings
Shares of Horizon Pharma (NASDAQ: HZNP  ) are down almost 5% in premarket this morning after the company missed revenue estimates by $2.08 million, or 6%. The company did beat on earnings by $0.04 due to the early termination of a senior loan facility in the fourth quarter related to the acquisition of Vimovo from AstraZeneca.

What investors are keying in on this morning are sales of Horizon's (NASDAQ: HZNP  ) flagship arthritis drug Duexis. Despite gross sales growing by 548% year over year, analysts expected slightly higher revenue in the fourth quarter. A closer look at the press release shows that this lower revenue from Duexis sales is tied to service fees paid to wholesale distributors in the quarter, which were higher than anticipated.

Looking ahead, Horizon (NASDAQ: HZNP  ) is expected to grow net revenue by a notable 80% to 100% in 2014, thereby achieving profitability on a non-GAAP basis. So, even though Horizon (NASDAQ: HZNP  ) shares are up 510% in the past year, there is good reason to believe this stock could continue to climb even higher. As such, you might want to dig deeper into this rising biopharma. 

Today's movers in biotech may have great potential, but they may have trouble keeping up with this top stock.
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

 


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 13, 2014, at 9:23 AM, jm123 wrote:

    Omg, Duexis service fees were NOT higher than anticipated. Its just new accounting method (you can not compare analysts estimates that are using old method with this real number). At least read the press release "Company's historical and audited classification of these services fees as a component of cost of goods sold. Subsequently, in connection with the audit of its 2013 financial results, the Company determined that these services fees should be recorded as a reduction in revenue rather than as an increase in cost of goods sold. The revision to the classification of these fees has the effect of reducing net revenue and cost of goods sold by the same dollar amount, with gross profit dollars unchanged, resulting in a higher gross profit margin on the reduced net sales amounts."...and also in CC they says that the difference in net sales was about 11 % because of this...so in real they beat on both, sales and profit...

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2874045, ~/Articles/ArticleHandler.aspx, 11/27/2014 4:40:33 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement